Showing results (91-100 of 167) with videos related to
Sort By:
Pageof 17
Plos One|August 26, 2021
To maximize or randomize? An experimental study of probability matching in financial decision makingAndrew W Lo, Katherine P Marlowe, Ruixun ZhangProceedings of the National Academy of Sciences of the United States of America|December 3, 2014
The origin of risk aversionRuixun Zhang, Thomas J Brennan, Andrew W LoThe Journal of Biological Chemistry|December 11, 2002
Human RNase H1 activity is regulated by a unique redox switch formed between adjacent cysteinesWalt F Lima, Hongjiang Wu, Josh G Nichols, et al.Nucleic Acid Therapeutics|January 16, 2024
Safety and Tolerability of GalNAc3-Conjugated Antisense Drugs Compared to the Same-Sequence 2'-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial DataBrenda F Baker, Shuting Xia, Wesley Partridge, et al.JCI Insight|March 20, 2025
A toxic gain-of-function variant in MAPK8IP3 provides insights into JIP3 cellular rolesWei Zhang, Swapnil Mittal, Ria Thomas, et al.Journal of Lipid Research|January 24, 2007
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic miceMark J Graham, Kristina M Lemonidis, Charles P Whipple, et al.Nature Biotechnology|October 2, 2012
Commercializing biomedical research through securitization techniquesJose-Maria Fernandez, Roger M Stein, Andrew W LoPLOS Global Public Health|March 24, 2023
Should we allocate more COVID-19 vaccine doses to non-vaccinated individuals?Zied Ben Chaouch, Andrew W Lo, Chi Heem WongBiostatistics (Oxford, England)|February 3, 2018
Estimation of clinical trial success rates and related parametersChi Heem Wong, Kien Wei Siah, Andrew W LoOrphanet Journal of Rare Diseases|July 15, 2025
A father's crusade in rare disease drug development: a case study of Elpida therapeutics and MelpidaDeanna Portero, Qingyang Xu, Aaliya Hussain, et al.Pageof 17